Immunic's drug IMU-856 shows promise in treating IBS with constipation, new trial data suggests.

Immunic, a pharmaceutical company, has published data from its Phase 1/1b trial of IMU-856 in a respected medical journal. The trial assessed the drug's safety and effectiveness in treating irritable bowel syndrome with constipation. Results indicate IMU-856 may be a promising treatment, showing good safety and tolerance in both healthy subjects and patients.

November 13, 2024
3 Articles